 Based on an internal strategic review and prioritization of its portfolio, Asklepios BioPharmaceutical Inc AskBio has decided to give all rights of methylmalonic acidemia MMA to Selecta Biosciences Inc NASDAQ: SELB. MMA program includes gene therapy candidate MMA-101 and ImmTOR for the treatment of methylmalonic acidemia MMA. 